/ Print /

PHARMACY BEST PRACTICES

Why Efforts to Curb Opioid Use Haven’t Translated to the Pediatric PopulationA new study shows efforts to reduce prescription opioid use in adults has not curtailed the incidence of pediatric opioid ingestions. Find out why.
Readmission Cost Savings are a Reality with Enhanced Patient EngagementReduce readmissions by focusing on better engagement with patients and improving coordination from inpatient to outpatient settings.
Migraine Pipeline and Impact Updates: What Health Execs Should Know
Migraine Pipeline and Impact Updates: What Health Execs Should KnowA new report highlights physical, social, and economic challenges of migraine.
Will UnitedHealthcare’s Direct-to-Consumer Pharma Rebates Curb Rising Costs?UnitedHealthcare will pass on pharmacy discounts directly to some consumers, signaling the next wave of disruption in healthcare, say industry watchers.
HIV Pipeline Prospects Getting HealthierThere is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Cigna-Express Scripts Deal: 5 Takeaways for Health ExecsThe Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.
Four New Ways to Approach Opioid Use DisordersA new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage.
Scammers, Fraudsters Capitalize on Opioid Addiction Treatment
Scammers, Fraudsters Capitalize on Opioid Addiction TreatmentA lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.
Seven diseases benefiting from genetic tests
Seven diseases benefiting from genetic testsGenetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
What Roche’s Purchase of Flatiron Health Means for Health ExecsSwitzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.